QT interval prolongation is so frequently associated with torsades de pointes (TdP) that it
has come to be recognized as a surrogate marker of this unique tachyarrhythmia. However …

Ranolazine is a novel antianginal agent capable of producing anti-ischemic effects at
plasma concentrations of 2 to 6 μM without a significant reduction of heart rate or blood …

Cellular electrophysiology experiments, important for understanding cardiac arrhythmia
mechanisms, are usually performed with channels expressed in non myocytes, or with non …

Background—Identification of patients at risk for drug-induced torsades de pointes
arrhythmia (TdP) is difficult. Increased temporal lability of repolarization has been suggested …

Putative interactions between the Human Ether-a-go-go Related Gene (HERG), QT interval
prolongation and Torsades de Pointes (TdP) are now integral components of any discussion …

Objectives: We investigated whether increasing or decreasing beat-to-beat variability of
repolarization (BVR) would change drug-induced proarrhythmic outcome accordingly …

The assessment of the torsadogenic potency of a new chemical entity is a crucial issue
during lead optimization and the drug development process. It is required by the regulatory …

Prolongation of the QT interval and the cardiac action potential have been linked to a
potentially fatal but rare tachyarrhythmia known as Torsades de Pointes (TdP). Nonclinical …

Proarrhythmic susceptibility to drug-induced Torsades de Pointes is restricted to individuals
with a predisposed phenotype characterized by a reduced repolarization reserve. Additional …

Purpose To evaluate in vitro and computationally model the effects of selected antipsychotic
drugs on several ionic currents that contribute to changes in the action potential in cardiac …